HALO Annual Operating Expenses
$299.32 M
+$46.04 M+18.18%
31 December 2023
Summary:
As of January 22, 2025, HALO annual total operating expenses is $299.32 million, with the most recent change of +$46.04 million (+18.18%) on December 31, 2023. During the last 3 years, it has risen by +$219.35 million (+274.28%). HALO annual operating expenses is now at all-time high.HALO Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
HALO Quarterly Operating Expenses
$77.46 M
+$2.95 M+3.96%
30 September 2024
Summary:
As of January 22, 2025, HALO quarterly total operating expenses is $77.46 million, with the most recent change of +$2.95 million (+3.96%) on September 30, 2024. Over the past year, it has increased by +$4.53 million (+6.21%). HALO quarterly operating expenses is now -8.18% below its all-time high of $84.36 million, reached on June 30, 2022.HALO Quarterly Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
HALO Operating Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +18.2% | +6.2% |
| 3 y3 years | +274.3% | +6.2% |
| 5 y5 years | +41.8% | +6.2% |
HALO Operating Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +248.1% | -8.2% | +224.3% |
| 5 y | 5-year | at high | +274.3% | -8.2% | +335.0% |
| alltime | all time | at high | -8.2% | +7602.3% |
Halozyme Therapeutics Operating Expenses History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $77.46 M(+4.0%) |
| June 2024 | - | $74.51 M(+3.5%) |
| Mar 2024 | - | $72.01 M(-6.1%) |
| Dec 2023 | $299.32 M(+18.2%) | $76.71 M(+5.2%) |
| Sept 2023 | - | $72.93 M(-4.7%) |
| June 2023 | - | $76.51 M(+4.6%) |
| Mar 2023 | - | $73.17 M(+12.8%) |
| Dec 2022 | $253.28 M(+194.5%) | $64.87 M(-17.2%) |
| Sept 2022 | - | $78.36 M(-7.1%) |
| June 2022 | - | $84.36 M(+228.4%) |
| Mar 2022 | - | $25.69 M(+7.6%) |
| Dec 2021 | $86.00 M(+7.5%) | $23.88 M(+10.3%) |
| Sept 2021 | - | $21.66 M(+6.2%) |
| June 2021 | - | $20.39 M(+1.6%) |
| Mar 2021 | - | $20.07 M(+12.7%) |
| Dec 2020 | $79.97 M(-63.3%) | $17.81 M(-8.4%) |
| Sept 2020 | - | $19.45 M(-2.4%) |
| June 2020 | - | $19.93 M(-12.6%) |
| Mar 2020 | - | $22.79 M(-67.0%) |
| Dec 2019 | $218.06 M(+3.3%) | $69.04 M(+42.5%) |
| Sept 2019 | - | $48.43 M(-5.5%) |
| June 2019 | - | $51.25 M(+3.9%) |
| Mar 2019 | - | $49.33 M(-9.8%) |
| Dec 2018 | $211.06 M(+3.2%) | $54.68 M(+8.5%) |
| Sept 2018 | - | $50.40 M(-7.4%) |
| June 2018 | - | $54.44 M(+5.6%) |
| Mar 2018 | - | $51.53 M(-8.2%) |
| Dec 2017 | $204.46 M(+3.9%) | $56.15 M(+18.6%) |
| Sept 2017 | - | $47.32 M(-8.0%) |
| June 2017 | - | $51.44 M(+3.8%) |
| Mar 2017 | - | $49.55 M(-7.5%) |
| Dec 2016 | $196.69 M(+47.6%) | $53.58 M(+17.8%) |
| Sept 2016 | - | $45.46 M(-2.8%) |
| June 2016 | - | $46.75 M(-8.2%) |
| Mar 2016 | - | $50.91 M(+32.8%) |
| Dec 2015 | $133.26 M(+15.2%) | $38.34 M(+1.3%) |
| Sept 2015 | - | $37.84 M(+22.0%) |
| June 2015 | - | $31.01 M(+18.9%) |
| Mar 2015 | - | $26.08 M(-7.1%) |
| Dec 2014 | $115.64 M(-10.3%) | $28.08 M(-1.4%) |
| Sept 2014 | - | $28.49 M(+4.0%) |
| June 2014 | - | $27.40 M(-13.5%) |
| Mar 2014 | - | $31.66 M(+4.6%) |
| Dec 2013 | $128.99 M | $30.28 M(-10.5%) |
| Sept 2013 | - | $33.82 M(-4.2%) |
| June 2013 | - | $35.29 M(+19.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2013 | - | $29.59 M(+15.8%) |
| Dec 2012 | $94.86 M(+25.4%) | $25.55 M(+1.6%) |
| Sept 2012 | - | $25.14 M(+16.0%) |
| June 2012 | - | $21.66 M(-3.8%) |
| Mar 2012 | - | $22.51 M(+8.3%) |
| Dec 2011 | $75.67 M(+13.1%) | $20.78 M(+16.9%) |
| Sept 2011 | - | $17.78 M(-10.7%) |
| June 2011 | - | $19.91 M(+15.8%) |
| Mar 2011 | - | $17.19 M(-16.4%) |
| Dec 2010 | $66.90 M(-6.9%) | $20.57 M(+30.0%) |
| Sept 2010 | - | $15.82 M(+3.5%) |
| June 2010 | - | $15.28 M(+0.4%) |
| Mar 2010 | - | $15.22 M(-19.7%) |
| Dec 2009 | $71.82 M(+22.0%) | $18.96 M(+12.4%) |
| Sept 2009 | - | $16.87 M(-8.7%) |
| June 2009 | - | $18.46 M(+5.4%) |
| Mar 2009 | - | $17.53 M(-12.2%) |
| Dec 2008 | $58.87 M(+85.6%) | $19.96 M(+47.5%) |
| Sept 2008 | - | $13.53 M(+5.9%) |
| June 2008 | - | $12.77 M(+1.3%) |
| Mar 2008 | - | $12.60 M(+12.2%) |
| Dec 2007 | $31.71 M(+96.6%) | $11.24 M(+22.2%) |
| Sept 2007 | - | $9.19 M(+42.2%) |
| June 2007 | - | $6.47 M(+34.3%) |
| Mar 2007 | - | $4.81 M(-4.7%) |
| Dec 2006 | $16.13 M(+18.3%) | $5.05 M(+31.9%) |
| Sept 2006 | - | $3.83 M(+8.9%) |
| June 2006 | - | $3.52 M(-5.5%) |
| Mar 2006 | - | $3.72 M(+3.0%) |
| Dec 2005 | $13.64 M(+50.1%) | $3.61 M(-4.4%) |
| Sept 2005 | - | $3.78 M(+27.3%) |
| June 2005 | - | $2.97 M(-9.2%) |
| Mar 2005 | - | $3.27 M(+29.4%) |
| Dec 2004 | $9.09 M(>+9900.0%) | $2.53 M(-22.5%) |
| Sept 2004 | - | $3.26 M(+56.2%) |
| June 2004 | - | $2.09 M(+73.0%) |
| Mar 2004 | - | $1.21 M(-217.0%) |
| Dec 2003 | $0.00(0.0%) | -$1.03 M(-352.9%) |
| Sept 2003 | - | $408.20 K(+9.5%) |
| June 2003 | - | $372.90 K(+48.3%) |
| Mar 2003 | - | $251.40 K(-532.7%) |
| Dec 2002 | $0.00(-100.0%) | -$58.10 K(-326.1%) |
| Sept 2002 | - | $25.70 K(+38.2%) |
| June 2002 | - | $18.60 K(+35.8%) |
| Mar 2002 | - | $13.70 K |
| Dec 2001 | $48.50 K | - |
FAQ
- What is Halozyme Therapeutics annual total operating expenses?
- What is the all time high annual operating expenses for Halozyme Therapeutics?
- What is Halozyme Therapeutics annual operating expenses year-on-year change?
- What is Halozyme Therapeutics quarterly total operating expenses?
- What is the all time high quarterly operating expenses for Halozyme Therapeutics?
- What is Halozyme Therapeutics quarterly operating expenses year-on-year change?
What is Halozyme Therapeutics annual total operating expenses?
The current annual operating expenses of HALO is $299.32 M
What is the all time high annual operating expenses for Halozyme Therapeutics?
Halozyme Therapeutics all-time high annual total operating expenses is $299.32 M
What is Halozyme Therapeutics annual operating expenses year-on-year change?
Over the past year, HALO annual total operating expenses has changed by +$46.04 M (+18.18%)
What is Halozyme Therapeutics quarterly total operating expenses?
The current quarterly operating expenses of HALO is $77.46 M
What is the all time high quarterly operating expenses for Halozyme Therapeutics?
Halozyme Therapeutics all-time high quarterly total operating expenses is $84.36 M
What is Halozyme Therapeutics quarterly operating expenses year-on-year change?
Over the past year, HALO quarterly total operating expenses has changed by +$4.53 M (+6.21%)